Multiple studies have shown that ketamine is a fast acting treatment for depression, but a key issue with the studies is that many participants can tell...
Following all the hype generated about the therapeutic powers of psychedelics by Michael Pollan’s 2018 book How to Change Your Mind and follow up 2022 Netflix...
Diamond Therapeutics has announced that the first patient has been enrolled in its FDA-authorised UAB-Diamond trial evaluating low-dose psilocybin in patients with demoralization.
Awakn Life Sciences recently announced the completion of its feasibility study for its proprietary formulation of MDMA using Catalent’s Zydis® orally disintegrating tablet (ODT) technology.
New research has revealed that MDMA and methamphetamine deepen personal connections following guided conversations, and suggests different mechanisms for how these drugs produce feelings of closeness.
A team of researchers has analysed the experience of people with Obsessive-Compulsive Disorder (OCD) who have taken psychedelics, finding 30% experienced relief from their symptoms.
Results from a new analysis have revealed an improvement in mental health and cognition for Special Operations Forces veterans following a combination of psychedelic treatments.
Results from a major clinical trial have shown that esketamine outperforms one of the standard treatments for treatment-resistant major depression disorder (MDD).
Researchers from the University of Southern Denmark have established a psilocybin microdosing regimen in rats to help advance microdosing research.
Canada’s non-profit advocacy organisation TheraPsil has announced the launch of its MDMA-assisted psychotherapy training programme.